Dyne Therapeutics Inc. announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial evaluating zeleciment basivarsen (formerly DYNE-101) in patients with myotonic dystrophy type 1 (DM1). The results demonstrated clinically meaningful improvements in function and strength at the selected registrational dose, with both patients and physicians reporting reductions in overall disease burden. These findings were presented at the 30th Annual International Congress of the World Muscle Society $(WMS)$, held virtually and in Vienna, Austria, from October 7-11, 2025. Poster presentations and symposium materials are available on Dyne's website in the Scientific Publications & Presentations section.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9540973-en) on October 06, 2025, and is solely responsible for the information contained therein.